Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, cytarabine, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed acute myeloid leukemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cytarabine; Etoposide; Mitoxantrone

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of acute myeloid leukemia

• Previously untreated disease

• Previous hydroxyurea and/or corticosteroids are acceptable

• No preexisting history of a hematologic disorder

• Myelodysplastic features allowed

• No acute leukemia secondary to previous therapy

• No leukemic meningitis

PATIENT CHARACTERISTICS:

• Bilirubin < 2.0 mg/dL (unless felt to be increased because of hepatic infiltration with leukemia)

• Creatinine < 2.0 mg/dL

• Pregnant or lactating patients are ineligible

• Fertile patients must use effective contraception

• No history of or active congestive heart failure

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics